<DOC>
	<DOCNO>NCT02369029</DOCNO>
	<brief_summary>This first study BAY1238097 give human . Impact study evaluate patient advance cancer show clinical benefit treatment BET ( Bromodomain extraterminal domain family ) inhibitor.Patients solid tumor ( comer ) lymphoma receive study drug treatment escalation scheme ( placebo group ) determine safety , tolerability maximum tolerate dose ( MTD ) BAY1238097 . relative bioavailability Liquid Service Formulation tablet determine After MTD define , patient solid tumor ( comer , hepato cellular carcinoma , lung cancer , NUT ( nuclear protein testis ) -midline carcinoma ) , melanoma lymphoma enrol A separate escalation scheme apply patient leucemias , maximal tolerate dose , patient AML amd multiple myeloma enrol . study also assess pharmacokinetics , biomarker status , pharmacodynamic parameter BAY1238097 tumor response treatment . BAY1238097 give twice weekly oral application . Treatment stop tumor continue grow , side effect occur , wich patient tolerate patient decide withdraw treatment .</brief_summary>
	<brief_title>BAY1238097 , First Man</brief_title>
	<detailed_description />
	<criteria>Subjects advance , histologically cytologically confirm tumor , refractory standard treatment , standard therapy available , standard therapy therapeutic option subject actively refuse use chemotherapy would regard standard and/or judgment investigator , experimental treatment clinically ethically acceptable . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy least 12 week Adequate liver renal function assess follow laboratory requirement conduct within 7 day prior start study treatment : Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN ( ≤ 5 x ULN subject hepatic involvement tumor ) Amylase lipase ≤ 2.5 x ULN ( ≤ 5 x ULN subject pancreas involvement tumor ) Prothrombin time ( PTINR ) / partial thromboplastin time ( PTT ) ≤ 1.5 x ULN . Subjects therapeutically treat agent warfarin heparin allow participate provide prior evidence underlie abnormality coagulation parameter exist . Close monitoring least weekly evaluation perform INR stable base measurement pre dose define local standard care Estimated glomerular filtration rate ( eGFR ) ≥ 60 mL/min per 1.73 m2 accord Modification Diet Renal Disease Study Group ( MDRD ) formula ( see Section 14.6 ) Adequate cardiac function ( left ventricular ejection fraction [ LVEF ] ≥50 % measure echocardiography multigated acquisition [ MUGA ] scan ) History cardiac disease include congestive heart failure New York Heart Association ( NYHA ) Class &gt; II ( Section 14.7 ) , unstable angina ( anginal symptom rest ) newonset angina ( within last 6 month ) myocardial infarction within past 6 month cardiac arrhythmia require antiarrhythmic therapy except betablockers digoxin ; evidence uncontrolled coronary artery disease ( eg angina pectoris , myocardial infarction within 6 month prior study entry , major regional wall motion abnormality upon baseline echocardiography ) Moderate severe hepatic impairment , ie ChildPugh B C Restrictive lung disease due parenchymal damage ( eg idiopathic lung fibrosis ) pleural adhesion . Patients lung resection , scoliosis thorax malformation include provided adequate spirometry test screening ( eg FEVForced expiratory volume 1 ≥ 70 % ; age , sex height adapt vital capacity ) Evidence history bleed diathesis . Any hemorrhage/bleeding event ≥ CTCAE ( Common terminology criterion adverse event ) Grade 3 within 4 week first dose study drug Human immunodeficiency virus ( HIV ) infection Chronic active hepatitis B C ( patient positive HBsAg HBcAb eligible negative HBVDNA ; patient positive HCVAb eligible negative HCVRNA ) History malignancy could affect compliance protocol interpretation result . Patients history curatively treat nonmelanoma skin cancer situ carcinoma cervix breast allow . Patients malignancy treat curative intent also allow malignancy complete remission without treatment least 1 year prior Cycle 1 Day 1 study treatment . A recent history myelodysplastic syndrome patient secondary leukemia allow Autologous bone marrow transplant stem cell rescue within 4 month study entry Any condition unstable could jeopardize safety patient his/her compliance study Anticancer chemotherapy immunotherapy study within less 3 halflives anticancer chemotherapy 6 week antibody therapy ( 2 week leukemia patient ) prior start study drug . Use strong CYP3A4 inhibitor ketoconazole , itraconazole , clarithromycin , ritonavir , indinavir , nelfinavir , saquinavir ( see Table 6 6 ) 14 day first dose study drug study Use strong CYP3A4 inducer rifampin , St John 's Wort , herbal preparation contain strong CYP3A4 inducer ( see Table 6 6 ) 14 day first dose study drug study Clinically relevant finding ECG seconddegree thirddegree atrioventricular ( AV ) block ( subject AV block pacemaker place &gt; 1 year check cardiologist within ≤6 month first dose study drug exclude ) , prolongation QRS complex 120 msec QTc interval ( Fridericia , QTcF ) 470 msec ( subject pacemaker QRS interval 120 msec QTc inverval 470 msec may enrol casebycase basis , follow discussion investigator sponsor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>NUT-midline carcinoma</keyword>
	<keyword>Acute Leucemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>HCC</keyword>
	<keyword>NSCLC</keyword>
</DOC>